, ,
Aruna Bio

A Revolutionary New Therapy For The $5.1B Stroke Treatment Industry

About this Event

Every 40 seconds someone in the United States has a stroke. Yet the current standard of care helps only 15% of stroke victims.

Aruna Bio is a pioneer in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases and events that include ALS, Parkinson’s, Alzheimer’s, and Stroke. The company has produced AB126, the first exosome to receive an IND clearance from the FDA for a neurological disease and plans to initiate a Phase 1b/2a clinical trial in acute ischemic stroke in the first half of 2024.

AB126 acts differently than current treatments in that it’s not removing the clot; it’s reducing the inflammation in the brain caused by the stroke. When someone has a stroke, their brain cells start dying and release damaging particles that cause extensive inflammation. AB126 mops up those damaging particles which prevents other brain cells from dying due to inflammation. Because of the lack of treatment options for 85% of ischemic stroke patients, AB126 has a unique opportunity to become the standard of care in the $5.1 billion acute ischemic stroke diagnosis and treatment industry.

Watch the webinar with Aruna Bio CEO, Steven From, to learn how AB126 has both native therapeutic benefits and can transport other molecules directly to neural cells, creating multiple shots on goal for this drug delivery platform.

Hosted by Steven Saltzstein, CEO, Force Family Office

Video On Demand

– Recorded

April 17

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.